Conversion from sildenafil to tadalafil: Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study

Robert Frantz, Louise Durst, Charles Dwayne Burger, Ronald J. Oudiz, Robert C. Bourge, Veronica Franco, Aaron B. Waxman, Susanne McDevitt, Susan Walker

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary arterial hypertension (PAH). This study assessed the safety and patient satisfaction with conversion from sildenafil to tadalafil.

Methods: In this multicenter, prospective, 6-month study, patients with PAH were instructed to take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d the next morning. Patients completed the Treatment Satisfaction Questionnaire for Medication at baseline and 30, 90, and 180 days after transition to assess PAH symptoms and patient satisfaction. Safety was assessed on the basis of recorded adverse events (AEs).

Results: Of the 35 patients who met the study criteria, 56% were receiving ≥2 PAH therapies. At the time of transition, the sildenafil dose ranged from 40 to 300 mg/d, with 20% of the patients on >20 mg of sildenafil 3 times daily. Transition to tadalafil was generally well tolerated, and the incidence of common AEs, except for myalgia, appeared to decrease over time on tadalafil therapy. Five (14%) patients switched back to sildenafil. A greater percentage of patients were satisfied than were dissatisfied after conversion to tadalafil (55% vs 19% at 90 days), while 26% felt about the same degree of satisfaction.

Conversion to tadalafil resulted in significant improvement in patient ratings of therapy convenience. Conclusions: Transition of patients from sildenafil to tadalafil was usually well tolerated, with improved convenience and may enhance treatment satisfaction.

Original languageEnglish (US)
Pages (from-to)550-557
Number of pages8
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume19
Issue number6
DOIs
StatePublished - Nov 11 2014

Fingerprint

Pulmonary Hypertension
Patient Satisfaction
Therapeutics
Safety
Phosphodiesterase 5 Inhibitors
Patient Transfer
Sildenafil Citrate
Tadalafil
Myalgia
Incidence

Keywords

  • patient satisfaction
  • pulmonary arterial hypertension
  • sildenafil
  • switch
  • tadalafil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Conversion from sildenafil to tadalafil : Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. / Frantz, Robert; Durst, Louise; Burger, Charles Dwayne; Oudiz, Ronald J.; Bourge, Robert C.; Franco, Veronica; Waxman, Aaron B.; McDevitt, Susanne; Walker, Susan.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 19, No. 6, 11.11.2014, p. 550-557.

Research output: Contribution to journalArticle

Frantz, Robert ; Durst, Louise ; Burger, Charles Dwayne ; Oudiz, Ronald J. ; Bourge, Robert C. ; Franco, Veronica ; Waxman, Aaron B. ; McDevitt, Susanne ; Walker, Susan. / Conversion from sildenafil to tadalafil : Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2014 ; Vol. 19, No. 6. pp. 550-557.
@article{dafd69cba83645539b10440316dbc644,
title = "Conversion from sildenafil to tadalafil: Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study",
abstract = "Purpose: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary arterial hypertension (PAH). This study assessed the safety and patient satisfaction with conversion from sildenafil to tadalafil.Methods: In this multicenter, prospective, 6-month study, patients with PAH were instructed to take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d the next morning. Patients completed the Treatment Satisfaction Questionnaire for Medication at baseline and 30, 90, and 180 days after transition to assess PAH symptoms and patient satisfaction. Safety was assessed on the basis of recorded adverse events (AEs).Results: Of the 35 patients who met the study criteria, 56{\%} were receiving ≥2 PAH therapies. At the time of transition, the sildenafil dose ranged from 40 to 300 mg/d, with 20{\%} of the patients on >20 mg of sildenafil 3 times daily. Transition to tadalafil was generally well tolerated, and the incidence of common AEs, except for myalgia, appeared to decrease over time on tadalafil therapy. Five (14{\%}) patients switched back to sildenafil. A greater percentage of patients were satisfied than were dissatisfied after conversion to tadalafil (55{\%} vs 19{\%} at 90 days), while 26{\%} felt about the same degree of satisfaction.Conversion to tadalafil resulted in significant improvement in patient ratings of therapy convenience. Conclusions: Transition of patients from sildenafil to tadalafil was usually well tolerated, with improved convenience and may enhance treatment satisfaction.",
keywords = "patient satisfaction, pulmonary arterial hypertension, sildenafil, switch, tadalafil",
author = "Robert Frantz and Louise Durst and Burger, {Charles Dwayne} and Oudiz, {Ronald J.} and Bourge, {Robert C.} and Veronica Franco and Waxman, {Aaron B.} and Susanne McDevitt and Susan Walker",
year = "2014",
month = "11",
day = "11",
doi = "10.1177/1074248414528066",
language = "English (US)",
volume = "19",
pages = "550--557",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Conversion from sildenafil to tadalafil

T2 - Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study

AU - Frantz, Robert

AU - Durst, Louise

AU - Burger, Charles Dwayne

AU - Oudiz, Ronald J.

AU - Bourge, Robert C.

AU - Franco, Veronica

AU - Waxman, Aaron B.

AU - McDevitt, Susanne

AU - Walker, Susan

PY - 2014/11/11

Y1 - 2014/11/11

N2 - Purpose: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary arterial hypertension (PAH). This study assessed the safety and patient satisfaction with conversion from sildenafil to tadalafil.Methods: In this multicenter, prospective, 6-month study, patients with PAH were instructed to take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d the next morning. Patients completed the Treatment Satisfaction Questionnaire for Medication at baseline and 30, 90, and 180 days after transition to assess PAH symptoms and patient satisfaction. Safety was assessed on the basis of recorded adverse events (AEs).Results: Of the 35 patients who met the study criteria, 56% were receiving ≥2 PAH therapies. At the time of transition, the sildenafil dose ranged from 40 to 300 mg/d, with 20% of the patients on >20 mg of sildenafil 3 times daily. Transition to tadalafil was generally well tolerated, and the incidence of common AEs, except for myalgia, appeared to decrease over time on tadalafil therapy. Five (14%) patients switched back to sildenafil. A greater percentage of patients were satisfied than were dissatisfied after conversion to tadalafil (55% vs 19% at 90 days), while 26% felt about the same degree of satisfaction.Conversion to tadalafil resulted in significant improvement in patient ratings of therapy convenience. Conclusions: Transition of patients from sildenafil to tadalafil was usually well tolerated, with improved convenience and may enhance treatment satisfaction.

AB - Purpose: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary arterial hypertension (PAH). This study assessed the safety and patient satisfaction with conversion from sildenafil to tadalafil.Methods: In this multicenter, prospective, 6-month study, patients with PAH were instructed to take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d the next morning. Patients completed the Treatment Satisfaction Questionnaire for Medication at baseline and 30, 90, and 180 days after transition to assess PAH symptoms and patient satisfaction. Safety was assessed on the basis of recorded adverse events (AEs).Results: Of the 35 patients who met the study criteria, 56% were receiving ≥2 PAH therapies. At the time of transition, the sildenafil dose ranged from 40 to 300 mg/d, with 20% of the patients on >20 mg of sildenafil 3 times daily. Transition to tadalafil was generally well tolerated, and the incidence of common AEs, except for myalgia, appeared to decrease over time on tadalafil therapy. Five (14%) patients switched back to sildenafil. A greater percentage of patients were satisfied than were dissatisfied after conversion to tadalafil (55% vs 19% at 90 days), while 26% felt about the same degree of satisfaction.Conversion to tadalafil resulted in significant improvement in patient ratings of therapy convenience. Conclusions: Transition of patients from sildenafil to tadalafil was usually well tolerated, with improved convenience and may enhance treatment satisfaction.

KW - patient satisfaction

KW - pulmonary arterial hypertension

KW - sildenafil

KW - switch

KW - tadalafil

UR - http://www.scopus.com/inward/record.url?scp=84908879696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908879696&partnerID=8YFLogxK

U2 - 10.1177/1074248414528066

DO - 10.1177/1074248414528066

M3 - Article

C2 - 24742768

AN - SCOPUS:84908879696

VL - 19

SP - 550

EP - 557

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 6

ER -